Our real-world findings indicate that most patients undergoing multiple lines of therapy experience persistent treatment refractoriness and low response rates,” the researchers wrote.

The global CD Antigen Cancer Therapy Market is valued at USD 27.5 Billion in 2024 and is projected to reach a value of USD 54 ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) ...